Laigo Bio

Laigo Bio is an early-stage biotechnology company headquartered in the Netherlands, pioneering the use of E3 ligase-induced internalization and selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTACs™ platform enables the generation of bispecific antibodies that pair optimal E3 ligases with pathogenic target proteins to stimulate their ubiquitination and lysosomal degradation with high specificity. Compared to traditional treatments, degrading target proteins achieves deeper inhibition of disease pathways while protecting healthy tissues and minimizing side effects.